Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a surprise result with important implications for cardiovascular drug research.
An article from
Dive Brief
Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a result with important implications for cardiovascular drug research.
Published Sept. 5, 2026
Pelacarsen, a liproprotein(a)-lowering drug from Novartis and Ionis Pharmaceuticals, failed a closely watched clinical trial on Sept. 4, 2026.
Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly
Novartis, Ionis Tumble On Surprise Flop For Heart Drug
Novartis Drug Fails Key Test for New Heart Disease Approach
‘Not the results we hoped for’: Lp(a)-lowering drug pelacarsen fails to reduce CV events
Cholesterol drug setback casts doubt over multibillion-dollar race
Another heart drug fails, shocking cardiologists
Novartis Heart Drug Failure Rattles Market for Rival Treatments
Novartis' Phase 3 cardiovascular study miss raises the stakes for Amgen, Lilly
A Zurigo Novartis in calo, farmaco cardiovascolare non supera il test finale
Updated: Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drug
Pelacarsen lowered Lp(a) levels in more than 8,000 patients but did not reduce the risk of heart attacks, strokes, or…
Novartis' Ionis-partnered Lp(a) blocker failed in testing. Both stocks fell.
(Bloomberg) -- A Novartis AG drug billed as a potential blockbuster failed to reduce the risk of heart attacks and strokes in a…
The Lp(a)HORIZON trial of pelacarsen, the first cardiovascular outcomes trial for an agent designed to lower lipoprotein(a),…
Novartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer heart attacks and…
Medical specialists are reeling after experimental medication did not pass a massive clinical trial, upending hopes for a new era…
